Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming ...

By Paul Arnold, Maggie Fick ZURICH (Reuters) -Swiss drugmaker Roche has abandoned global diverse workforce targets and ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

The building, designed by the renowned Swiss architectural firm Herzog & de Meuron, is 52 metres higher than the Prime Tower in Zurich. Roche plans to construct an even bigger 205-metre research ...

ZURICH (Reuters) -Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects ...

ZURICH, March 19 (Reuters) - Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse panels for U.S. hiring, the latest companies ...

ZURICH, March 12 (Reuters) - Roche (ROG.S), opens new tab has acquired rights to an obesity therapy by Denmark's Zealand Pharma (ZELA.CO), opens new tab in a collaboration deal worth up to $5.3 ...

Swiss Drugmakers Novartis and Roche Ditch Some Diversity Programmes on US Concerns By Paul Arnold, Maggie Fick ZURICH (Reuters) -Swiss drugmaker Roche has abandoned global diverse workforce ...